BioNTech
NEWS
Biopharma companies who have COVID-19 vaccines in development, have astonished skeptics by the speed with which they have developed vaccines.. But now comes an even more daunting challenge—scaling up manufacturing and distribution.
The United Kingdom’s Medicines & Healthcare Products Regulatory Agency granted temporary authorization for emergency use to Pfizer and BioNTech for their COVID-19 mRNA vaccine, BNT162b2.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 1, 2020.
Despite the constant need for social distancing, mask-wearing, and the isolation and economic uncertainty that resulted from the outbreak, there is still much to be thankful for when families gather around a virtual table to break bread and carve the turkey this year.
The Pfizer-BioNTech vaccine (now Comirnaty®) was fully approved by the U.S. Food and Drug Administration (FDA) on August 23 and boosters of this shot are now available to the most vulnerable Americans.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 24, 2020.
As expected after Pfizer and BioNTech announced their COVID-19 vaccine Phase III trial had completed and demonstrated a 95% efficacy rate, the companies plan to apply for an Emergency Use Authorization (EUA) with the FDA.
In addition to coming sooner than expected, the results are even better than expected. The trial hit all primary efficacy endpoints.
There are similarities between the two COVID-19 vaccine candidates, and a few differences. Here’s a look.
JOBS
IN THE PRESS